Inflection Biosciences

Inflection Biosciences is an Ireland-based company that develops small-molecule therapeutics for the treatment of cancer.

Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address major unmet needs in cancer. With bases in Dublin and London, the company is dedicated to identifying excellent early stage cancer research from academic institutes and companies around the world. Inflection Biosciences will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering with larger. pharma for later stage clinical development and commercialisation. The company’s founders, including CEO Darren Cunningham and Director of R&D Dr. Michael O’Neill, bring over 60 years of industry experience along with access to a global network of potential partners and service providers.